67812-42-4
67812-42-4 結(jié)構(gòu)式
基本信息
鹽酸去甲維拉帕米
去甲維拉帕米鹽酸鹽
鹽酸去甲維拉帕米(N-去甲 鹽酸維拉帕米)
NORVERAPAMIL HYDROCHLORIDE
n-nor-(±)-verapamil hydrochloride
(±)-Norverapamill hydrochloride solution
(+/-)-VERAPAMIL, NOR-METHYL-, HYDROCHLORIDE
NorverapaMil HCl (N-DesMethyl VerapaMil HCl)
(+-)-VERAPAMIL HYDROCHLORIDE, NOR-METHYL (NORVERAPAMIL HYDROCH
a-[3-[[2-(3,4-Dimethoxyphenyl)ethyl]amino]propyl]-3,4-dimethoxy-a-(1-methylethyl)- benzeneacetonitril
a-[3-[[2-(3,4-Dimethoxyphenyl)ethyl]amino]propyl]-3,4-dimethoxy-a-(1-methylethyl)-benzeneacetonitrile
α-[3-[[2-(3,4-Dimethoxyphenyl)ethyl]amino]propyl]-3,4-dimethoxy-α-(1-methylethyl)- benzeneacetonitrile
物理化學(xué)性質(zhì)
常見問題列表
Calcium channel blocker
P-glycoprotein (P-gp) inhibitor
Norverapamil hydrochloride ((±)-Norverapamil hydrochloride) is similarly effective as verapamil at inhibiting isoniazid and rifampicin tolerance and killing of intracellular M. tuberculosis in the absence of other drugs. norverapamil, also inhibits macrophage-induced tolerance and achieves similar serum levels to verapamil.
Verapamil and its major metabolite norverapamil were identified to be both mechanism-based inhibitors and substrates of CYP3A and reported to have non-linear pharmacokinetics in clinic.
Norverapamil hydrochloride (9 mg/kg; p.o.), a major metabolite of verapamil, has terminal half-life, AUC and Cmax values of 9.4 hours, 260 ng?h/ml, and 41.6 ng/mL, respectively.
| Animal Model: | Male Sprague-Dawley rats |
| Dosage: | 9 mg/kg (Pharmacokinetic Study) |
| Administration: | Oral administration |
| Result: | t 1/2 =9.4 hours; AUC=260 ng?h/mL; C max =41.6 ng/mL. |